Psoriatic Arthritis News

MADRID — Many patients with psoriatic arthritis being treated with biologic therapy reported ongoing pain, according to findings from a real-world data set presented at the EULAR Annual Congress.

MADRID — Two different dosing levels of tofacitinib bested placebo in response rate and safety parameters for patients with psoriatic arthritis, according to findings presented at the EULAR Annual Congress.

MADRID — Improvements in arthritis outcomes, physical function and psoriasis were reported for treatment with ixekizumab among patients with active psoriatic arthritis, according to findings presented at the EULAR Annual Congress.

MADRID — The presence of baseline comorbidities was associated with adverse outcomes in psoriatic arthritis, including poor response to and discontinuation of tumor necrosis factor inhibitors, according to findings presented at the EULAR Annual Congress.

An expert panel recommended guidelines for patients with pediatric psoriasis, including routine screening and identification of certain risk factors for associated comorbidities, according to a consensus statement published in JAMA Dermatology.

Sandoz’s proposed biosimilars to Humira and Remicade were accepted for regulatory review by the European Medicines Agency, according to a company release.

Otezla demonstrated an acceptable safety profile through at least 3 years of treatment among patients with psoriasis, according to recently published study results in the Journal of the American Academy of Dermatology.

“In agreement with other clinical trials investigating biologics targeting interleukin-17A signaling, these data further verify the role of interleukin-17A in the promotion of the pathogenesis of psoriatic arthritis,” Peter Nash, MD, from the University of Queensland in Australia, and colleagues wrote.

Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when to prescribe methotrexate to high-risk patients, according to recently published study results in the Journal of the American Academy of Dermatology.

Patients with ankylosing spondylitis, psoriatic arthritis or undifferentiated spondyloarthritis had greater risks for acute coronary syndrome and stroke events compared with the general population, according to a recently published prospective study.